257 related articles for article (PubMed ID: 20178967)
1. [Epidemiology of hepatitis C and human immunodeficiency virus infections among injecting drug users in Hungary--what's next?].
Gyarmathy VA; Rácz J
Orv Hetil; 2010 Mar; 151(10):365-71. PubMed ID: 20178967
[TBL] [Abstract][Full Text] [Related]
2. [Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) testing among injecting drug users].
Gyarmathy VA; Rácz J
Orv Hetil; 2011 Jan; 152(4):124-30. PubMed ID: 21224188
[TBL] [Abstract][Full Text] [Related]
3. [The efficacy of needle exchange programs in the prevention of HIV and hepatitis infection among injecting drug users].
Takács IG; Demetrovics Z
Psychiatr Hung; 2009; 24(4):264-81. PubMed ID: 19949245
[TBL] [Abstract][Full Text] [Related]
4. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users.
de Vos AS; van der Helm JJ; Prins M; Kretzschmar ME
Epidemics; 2012 Jun; 4(2):57-67. PubMed ID: 22664064
[TBL] [Abstract][Full Text] [Related]
5. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea.
Min JA; Yoon Y; Lee HJ; Choi J; Kwon M; Kim K; Lee CU; Kim DJ; Yun H
J Med Virol; 2013 Apr; 85(4):575-82. PubMed ID: 23364858
[TBL] [Abstract][Full Text] [Related]
7. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria.
Tun W; Vu L; Adebajo SB; Abiodun L; Sheehy M; Karlyn A; Njab J; Ahonsi B; Issa BK; Idogho O
Int J STD AIDS; 2013 Aug; 24(8):619-25. PubMed ID: 23970571
[TBL] [Abstract][Full Text] [Related]
8. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
9. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
[TBL] [Abstract][Full Text] [Related]
10. [Social networks, risk dyads, and their role in the epidemiology and prevention of drug related infectious diseases].
Gyarmathy VA; Rácz J
Orv Hetil; 2010 Aug; 151(32):1289-94. PubMed ID: 20656668
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
12. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
13. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010.
Wiessing L; Likatavicius G; Hedrich D; Guarita B; van de Laar MJ; Vicente J
Euro Surveill; 2011 Dec; 16(48):. PubMed ID: 22172300
[TBL] [Abstract][Full Text] [Related]
14. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.
van den Berg CH; Smit C; Bakker M; Geskus RB; Berkhout B; Jurriaans S; Coutinho RA; Wolthers KC; Prins M
Eur J Epidemiol; 2007; 22(3):183-93. PubMed ID: 17334821
[TBL] [Abstract][Full Text] [Related]
15. Liquid drugs and high dead space syringes may keep HIV and HCV prevalence high - a comparison of Hungary and Lithuania.
Gyarmathy VA; Neaigus A; Li N; Ujhelyi E; Caplinskiene I; Caplinskas S; Latkin CA
Eur Addict Res; 2010; 16(4):220-8. PubMed ID: 20798543
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
[TBL] [Abstract][Full Text] [Related]
18. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
Copeman M
Med J Aust; 2003 Jul; 179(2):119; author reply 119. PubMed ID: 12864712
[No Abstract] [Full Text] [Related]
19. Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus.
Demetriou VL; van de Vijver DA; Hezka J; Kostrikis LG; ; Kostrikis LG
J Med Virol; 2010 Feb; 82(2):263-70. PubMed ID: 20029809
[TBL] [Abstract][Full Text] [Related]
20. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China.
Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS
PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
